EN: Which drug prevents worsening of paroxysmal atrial fibrillation: verapamil or metoprolol? NL: Welk medicijn voorkomt het hardnekkiger worden van paroxismaal atriumfibrilleren: verapamil of metoprolol?

INTERVENTION: Patients are randomized to verapamil slow release 240mg once daily or metoprolol slow release 100mg once daily. Dose adjustments (half or double) can be made upon the response to heart rate or blood pressure. CONDITION: Atrial Fibrillation, Metoprolol, Verapamil ; ; PRIMARY OUTCOME: Primary outcome variable is incidence of AF progression from paroxysmal to persistent AF or the need for PVI. SECONDARY OUTCOME: Main secondary outcome variables are AF burden, heart rate, exercise tolerance, symptom severity, quality of life, and costs. INCLUSION CRITERIA: In order to be eligible to participate in this trial, a subject must meet all of the following criteria: Patients (age > 18) with symptomatic paroxysmal AF with an indication for rate control medication who participate in the RACE 5 registry. Patients must be able and willing to sign informed consent for the randomised study.